 Cynthia Epperson
Concepts (516)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenstrual Syndrome | 17 | 2023 | 27 | 5.370 |
Why?
| | Pregnancy Complications | 21 | 2018 | 431 | 4.520 |
Why?
| | Depression, Postpartum | 17 | 2022 | 102 | 3.990 |
Why?
| | Premenstrual Dysphoric Disorder | 12 | 2023 | 16 | 3.500 |
Why?
| | Menopause | 13 | 2023 | 262 | 3.450 |
Why?
| | Stress, Psychological | 13 | 2023 | 975 | 3.290 |
Why?
| | Sex Characteristics | 13 | 2021 | 644 | 3.220 |
Why?
| | Depressive Disorder, Major | 14 | 2023 | 307 | 3.060 |
Why?
| | Depression | 20 | 2023 | 1149 | 2.440 |
Why?
| | Brain | 18 | 2022 | 2382 | 2.090 |
Why?
| | Mood Disorders | 7 | 2020 | 117 | 2.090 |
Why?
| | Gonadal Steroid Hormones | 6 | 2018 | 124 | 2.080 |
Why?
| | gamma-Aminobutyric Acid | 11 | 2023 | 152 | 2.060 |
Why?
| | Mental Disorders | 10 | 2018 | 908 | 2.040 |
Why?
| | Executive Function | 8 | 2023 | 374 | 1.950 |
Why?
| | Female | 132 | 2023 | 60086 | 1.820 |
Why?
| | Reflex, Startle | 3 | 2022 | 58 | 1.720 |
Why?
| | Depressive Disorder | 8 | 2017 | 337 | 1.710 |
Why?
| | Prefrontal Cortex | 6 | 2018 | 267 | 1.710 |
Why?
| | Perimenopause | 4 | 2023 | 59 | 1.640 |
Why?
| | Prenatal Exposure Delayed Effects | 5 | 2019 | 449 | 1.610 |
Why?
| | Antidepressive Agents | 11 | 2018 | 195 | 1.540 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2023 | 116 | 1.500 |
Why?
| | Cognition | 8 | 2023 | 982 | 1.470 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2022 | 159 | 1.440 |
Why?
| | Menstrual Cycle | 9 | 2022 | 110 | 1.430 |
Why?
| | Pregnancy | 36 | 2023 | 5556 | 1.390 |
Why?
| | Memory, Short-Term | 6 | 2020 | 225 | 1.390 |
Why?
| | Biomedical Research | 3 | 2021 | 590 | 1.370 |
Why?
| | Humans | 144 | 2023 | 115908 | 1.360 |
Why?
| | Anxiety | 12 | 2022 | 853 | 1.350 |
Why?
| | Sex Factors | 13 | 2021 | 1741 | 1.320 |
Why?
| | Tryptophan | 7 | 2020 | 136 | 1.320 |
Why?
| | Stress, Physiological | 4 | 2019 | 397 | 1.270 |
Why?
| | Psychotherapy | 8 | 2018 | 149 | 1.150 |
Why?
| | Serotonin | 7 | 2020 | 296 | 1.140 |
Why?
| | Lower Urinary Tract Symptoms | 4 | 2020 | 47 | 1.140 |
Why?
| | Longevity | 2 | 2019 | 137 | 1.090 |
Why?
| | Lisdexamfetamine Dimesylate | 2 | 2016 | 4 | 1.080 |
Why?
| | Progesterone | 9 | 2023 | 232 | 1.060 |
Why?
| | Transgender Persons | 2 | 2018 | 135 | 1.050 |
Why?
| | Stress Disorders, Post-Traumatic | 5 | 2019 | 751 | 1.040 |
Why?
| | Postmenopause | 4 | 2023 | 301 | 1.030 |
Why?
| | Hypothalamo-Hypophyseal System | 6 | 2023 | 197 | 1.030 |
Why?
| | Smoking Cessation | 4 | 2022 | 378 | 1.010 |
Why?
| | Child Abuse | 3 | 2020 | 455 | 1.000 |
Why?
| | Estradiol | 11 | 2023 | 453 | 1.000 |
Why?
| | Adult | 68 | 2022 | 30820 | 0.990 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2018 | 43 | 0.980 |
Why?
| | Cross-Over Studies | 9 | 2022 | 437 | 0.970 |
Why?
| | Pregnant Women | 2 | 2018 | 132 | 0.960 |
Why?
| | Central Nervous System Stimulants | 2 | 2016 | 140 | 0.950 |
Why?
| | C-Reactive Protein | 2 | 2023 | 364 | 0.900 |
Why?
| | Psychiatric Status Rating Scales | 12 | 2022 | 485 | 0.890 |
Why?
| | Gender Identity | 3 | 2018 | 104 | 0.880 |
Why?
| | Urinalysis | 1 | 2023 | 62 | 0.870 |
Why?
| | Obsessive-Compulsive Disorder | 8 | 2010 | 32 | 0.850 |
Why?
| | Positron-Emission Tomography | 3 | 2020 | 290 | 0.850 |
Why?
| | Magnetic Resonance Imaging | 9 | 2023 | 3087 | 0.850 |
Why?
| | Ethics Committees, Research | 2 | 2020 | 38 | 0.850 |
Why?
| | Hydrocortisone | 3 | 2019 | 272 | 0.830 |
Why?
| | Pregnanolone | 6 | 2023 | 21 | 0.830 |
Why?
| | Pituitary-Adrenal System | 4 | 2019 | 162 | 0.820 |
Why?
| | Double-Blind Method | 14 | 2022 | 1665 | 0.810 |
Why?
| | Psychopharmacology | 1 | 2021 | 7 | 0.790 |
Why?
| | Prenatal Diagnosis | 1 | 2023 | 167 | 0.790 |
Why?
| | Transsexualism | 2 | 2018 | 17 | 0.780 |
Why?
| | Affect | 6 | 2023 | 244 | 0.770 |
Why?
| | Emotions | 5 | 2023 | 486 | 0.750 |
Why?
| | Estrogens | 4 | 2020 | 316 | 0.750 |
Why?
| | Cognition Disorders | 3 | 2017 | 478 | 0.730 |
Why?
| | Glutamic Acid | 5 | 2018 | 213 | 0.730 |
Why?
| | Sertraline | 4 | 2023 | 26 | 0.720 |
Why?
| | Therapy, Computer-Assisted | 3 | 2017 | 58 | 0.720 |
Why?
| | Tobacco Use Disorder | 1 | 2022 | 238 | 0.710 |
Why?
| | Attention | 2 | 2015 | 393 | 0.710 |
Why?
| | Life Change Events | 3 | 2017 | 135 | 0.700 |
Why?
| | Smoking | 5 | 2022 | 1468 | 0.690 |
Why?
| | Sleep Wake Disorders | 1 | 2023 | 234 | 0.690 |
Why?
| | Middle Aged | 39 | 2020 | 27084 | 0.680 |
Why?
| | Health Resources | 1 | 2020 | 122 | 0.660 |
Why?
| | Nicotine | 3 | 2022 | 267 | 0.650 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 5 | 2015 | 230 | 0.650 |
Why?
| | Interdisciplinary Research | 1 | 2019 | 25 | 0.650 |
Why?
| | Cost of Illness | 1 | 2020 | 258 | 0.630 |
Why?
| | Acoustic Stimulation | 2 | 2018 | 312 | 0.620 |
Why?
| | Resilience, Psychological | 1 | 2019 | 99 | 0.600 |
Why?
| | Patient Dropouts | 1 | 2018 | 65 | 0.600 |
Why?
| | Mental Health | 3 | 2022 | 573 | 0.590 |
Why?
| | Premature Birth | 4 | 2017 | 278 | 0.580 |
Why?
| | Immune System | 1 | 2018 | 173 | 0.570 |
Why?
| | Puerperal Disorders | 2 | 2010 | 31 | 0.570 |
Why?
| | Urinary Bladder, Overactive | 2 | 2019 | 20 | 0.570 |
Why?
| | Dementia | 2 | 2016 | 185 | 0.550 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 484 | 0.540 |
Why?
| | Young Adult | 20 | 2022 | 10518 | 0.540 |
Why?
| | Cigarette Smoking | 1 | 2017 | 80 | 0.520 |
Why?
| | Occipital Lobe | 5 | 2006 | 23 | 0.510 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 407 | 0.510 |
Why?
| | Male | 40 | 2023 | 56128 | 0.510 |
Why?
| | Treatment Outcome | 21 | 2022 | 9166 | 0.510 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2014 | 106 | 0.510 |
Why?
| | Postpartum Period | 6 | 2022 | 281 | 0.500 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 4670 | 0.500 |
Why?
| | Outpatients | 1 | 2018 | 328 | 0.490 |
Why?
| | Inflammation | 3 | 2023 | 2503 | 0.490 |
Why?
| | Bipolar Disorder | 3 | 2011 | 209 | 0.490 |
Why?
| | Monoamine Oxidase | 1 | 2014 | 27 | 0.480 |
Why?
| | Patient Acceptance of Health Care | 3 | 2017 | 682 | 0.480 |
Why?
| | Cytokines | 2 | 2019 | 1857 | 0.470 |
Why?
| | Luteal Phase | 5 | 2022 | 41 | 0.470 |
Why?
| | Quality of Life | 4 | 2019 | 2392 | 0.460 |
Why?
| | Patient Compliance | 1 | 2018 | 524 | 0.460 |
Why?
| | Platelet Aggregation | 1 | 2014 | 94 | 0.460 |
Why?
| | Memory | 2 | 2013 | 211 | 0.450 |
Why?
| | Antipsychotic Agents | 4 | 2006 | 183 | 0.450 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2013 | 10 | 0.450 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 496 | 0.440 |
Why?
| | Research Design | 2 | 2017 | 947 | 0.440 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 694 | 0.440 |
Why?
| | Estrus | 1 | 2012 | 12 | 0.430 |
Why?
| | Libido | 2 | 2023 | 24 | 0.420 |
Why?
| | Neurotransmitter Agents | 2 | 2018 | 77 | 0.420 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2012 | 22 | 0.420 |
Why?
| | Sexual Maturation | 1 | 2012 | 47 | 0.410 |
Why?
| | Seasonal Affective Disorder | 2 | 2011 | 9 | 0.410 |
Why?
| | Amines | 1 | 2012 | 38 | 0.410 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 503 | 0.410 |
Why?
| | Steroids | 2 | 2018 | 147 | 0.410 |
Why?
| | Adolescent | 16 | 2023 | 17955 | 0.400 |
Why?
| | Neuropsychological Tests | 7 | 2020 | 932 | 0.400 |
Why?
| | Neuroimaging | 4 | 2022 | 251 | 0.400 |
Why?
| | Smokers | 2 | 2022 | 147 | 0.400 |
Why?
| | Propylamines | 1 | 2011 | 11 | 0.390 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2011 | 13 | 0.390 |
Why?
| | Fluoxetine | 5 | 2006 | 46 | 0.380 |
Why?
| | Blood Platelets | 2 | 2004 | 350 | 0.380 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 336 | 0.370 |
Why?
| | Reproductive History | 1 | 2010 | 12 | 0.360 |
Why?
| | Memory Disorders | 1 | 2011 | 155 | 0.350 |
Why?
| | Aging | 3 | 2015 | 1640 | 0.350 |
Why?
| | Trichotillomania | 3 | 1999 | 6 | 0.350 |
Why?
| | Animals | 14 | 2020 | 32123 | 0.340 |
Why?
| | Pregnanes | 2 | 2006 | 3 | 0.340 |
Why?
| | Naltrexone | 1 | 2010 | 82 | 0.340 |
Why?
| | Behavior, Animal | 1 | 2012 | 471 | 0.330 |
Why?
| | Narcotic Antagonists | 1 | 2010 | 138 | 0.320 |
Why?
| | Oxygen | 1 | 2013 | 839 | 0.320 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2020 | 106 | 0.310 |
Why?
| | Hormone Replacement Therapy | 2 | 2018 | 77 | 0.310 |
Why?
| | Women's Health | 3 | 2017 | 271 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2020 | 0.310 |
Why?
| | Prevalence | 7 | 2022 | 2270 | 0.310 |
Why?
| | Anxiety Disorders | 3 | 2021 | 310 | 0.300 |
Why?
| | beta-Cyclodextrins | 2 | 2018 | 28 | 0.300 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 845 | 0.300 |
Why?
| | Reproducibility of Results | 5 | 2021 | 2814 | 0.290 |
Why?
| | Interleukin-6 | 2 | 2023 | 679 | 0.290 |
Why?
| | Phototherapy | 2 | 2004 | 24 | 0.290 |
Why?
| | Risk Factors | 8 | 2019 | 8714 | 0.270 |
Why?
| | Oxytocin | 2 | 1996 | 45 | 0.270 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2023 | 1138 | 0.270 |
Why?
| | Self Report | 3 | 2020 | 701 | 0.270 |
Why?
| | Pilot Projects | 5 | 2018 | 1374 | 0.260 |
Why?
| | Prolactin | 1 | 2006 | 95 | 0.260 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2018 | 125 | 0.250 |
Why?
| | Cross-Sectional Studies | 6 | 2023 | 4449 | 0.250 |
Why?
| | Gestational Age | 2 | 2023 | 757 | 0.250 |
Why?
| | Maternal Behavior | 2 | 2016 | 70 | 0.250 |
Why?
| | HIV Infections | 1 | 2019 | 2470 | 0.240 |
Why?
| | Risperidone | 3 | 2000 | 26 | 0.240 |
Why?
| | Puberty | 1 | 2006 | 137 | 0.240 |
Why?
| | Aged | 11 | 2020 | 19299 | 0.240 |
Why?
| | Hospitalization | 1 | 2013 | 1761 | 0.230 |
Why?
| | Epilepsy | 1 | 2008 | 290 | 0.230 |
Why?
| | Medicaid | 2 | 2018 | 411 | 0.230 |
Why?
| | Socioeconomic Factors | 4 | 2017 | 1090 | 0.220 |
Why?
| | Nocturia | 2 | 2020 | 7 | 0.220 |
Why?
| | Prenatal Care | 2 | 2017 | 257 | 0.220 |
Why?
| | United States | 8 | 2023 | 12338 | 0.210 |
Why?
| | Maternal Exposure | 1 | 2004 | 137 | 0.210 |
Why?
| | Pirenzepine | 2 | 1999 | 8 | 0.210 |
Why?
| | Child | 8 | 2020 | 18555 | 0.210 |
Why?
| | Health Status | 2 | 2020 | 733 | 0.210 |
Why?
| | Premenopause | 1 | 2023 | 104 | 0.210 |
Why?
| | Serotonin Antagonists | 3 | 2000 | 30 | 0.210 |
Why?
| | Comorbidity | 6 | 2018 | 1476 | 0.210 |
Why?
| | Medically Unexplained Symptoms | 1 | 2022 | 4 | 0.210 |
Why?
| | Consensus | 2 | 2016 | 533 | 0.210 |
Why?
| | Acoustics | 1 | 2022 | 55 | 0.210 |
Why?
| | Milk, Human | 1 | 2003 | 128 | 0.210 |
Why?
| | Sexual Behavior | 2 | 2023 | 442 | 0.200 |
Why?
| | Urination | 1 | 2022 | 40 | 0.200 |
Why?
| | Administration, Cutaneous | 3 | 2011 | 116 | 0.200 |
Why?
| | Longitudinal Studies | 3 | 2020 | 2437 | 0.200 |
Why?
| | Health Priorities | 1 | 2021 | 34 | 0.190 |
Why?
| | Contraceptive Agents | 1 | 2022 | 55 | 0.190 |
Why?
| | Urinary Bladder | 2 | 2020 | 165 | 0.190 |
Why?
| | Cohort Studies | 5 | 2020 | 4960 | 0.190 |
Why?
| | Pennsylvania | 2 | 2018 | 94 | 0.190 |
Why?
| | Norpregnadienes | 1 | 2020 | 7 | 0.190 |
Why?
| | Epigenesis, Genetic | 3 | 2020 | 531 | 0.190 |
Why?
| | Fatigue | 1 | 2022 | 295 | 0.190 |
Why?
| | RNA, Small Untranslated | 1 | 2020 | 15 | 0.190 |
Why?
| | Reward | 1 | 2023 | 208 | 0.190 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 11 | 0.180 |
Why?
| | White Matter | 1 | 2022 | 104 | 0.180 |
Why?
| | Contraception | 1 | 2022 | 118 | 0.180 |
Why?
| | Animal Care Committees | 1 | 2020 | 5 | 0.180 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 138 | 0.180 |
Why?
| | Cues | 1 | 2022 | 297 | 0.180 |
Why?
| | BRCA2 Protein | 1 | 2020 | 42 | 0.180 |
Why?
| | BRCA1 Protein | 1 | 2020 | 57 | 0.180 |
Why?
| | Spermatozoa | 1 | 2020 | 84 | 0.180 |
Why?
| | Nerve Net | 2 | 2020 | 228 | 0.180 |
Why?
| | Breast Feeding | 3 | 2014 | 371 | 0.180 |
Why?
| | Follow-Up Studies | 5 | 2018 | 4446 | 0.180 |
Why?
| | Ovariectomy | 1 | 2020 | 117 | 0.170 |
Why?
| | Hypogonadism | 1 | 2020 | 74 | 0.170 |
Why?
| | Menstruation | 2 | 2012 | 35 | 0.170 |
Why?
| | Administration, Oral | 2 | 2012 | 731 | 0.170 |
Why?
| | Sex Distribution | 1 | 2020 | 338 | 0.170 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 173 | 0.170 |
Why?
| | Cerebral Cortex | 1 | 2002 | 390 | 0.170 |
Why?
| | Propensity Score | 1 | 2020 | 225 | 0.170 |
Why?
| | Telemedicine | 2 | 2017 | 667 | 0.160 |
Why?
| | History, 20th Century | 1 | 2020 | 276 | 0.160 |
Why?
| | Receptors, GABA | 1 | 2018 | 9 | 0.160 |
Why?
| | Benzodiazepines | 3 | 2014 | 115 | 0.160 |
Why?
| | GABA Agonists | 1 | 2018 | 17 | 0.160 |
Why?
| | Protons | 2 | 2012 | 84 | 0.160 |
Why?
| | Fetus | 1 | 2023 | 703 | 0.160 |
Why?
| | Occupations | 1 | 2018 | 37 | 0.160 |
Why?
| | Gender Dysphoria | 1 | 2018 | 13 | 0.160 |
Why?
| | Cause of Death | 1 | 2020 | 369 | 0.160 |
Why?
| | Psychophysiology | 1 | 2018 | 15 | 0.160 |
Why?
| | Neurobiology | 1 | 2018 | 17 | 0.160 |
Why?
| | N-Acetylglucosaminyltransferases | 1 | 2018 | 23 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2018 | 86 | 0.150 |
Why?
| | Mothers | 2 | 2014 | 667 | 0.150 |
Why?
| | Obstetric Labor Complications | 1 | 2017 | 31 | 0.150 |
Why?
| | Melatonin | 2 | 2011 | 106 | 0.150 |
Why?
| | Glutamine | 2 | 2016 | 90 | 0.150 |
Why?
| | Population Surveillance | 1 | 2020 | 396 | 0.150 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 194 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 386 | 0.140 |
Why?
| | Self Concept | 1 | 2018 | 218 | 0.140 |
Why?
| | Child of Impaired Parents | 1 | 2017 | 40 | 0.140 |
Why?
| | Perinatal Care | 1 | 2017 | 38 | 0.140 |
Why?
| | Monitoring, Ambulatory | 1 | 2017 | 82 | 0.140 |
Why?
| | Family Conflict | 1 | 2017 | 37 | 0.140 |
Why?
| | Domestic Violence | 1 | 2017 | 44 | 0.140 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2016 | 3 | 0.140 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2016 | 10 | 0.140 |
Why?
| | Precision Medicine | 1 | 2020 | 356 | 0.140 |
Why?
| | Ecosystem | 1 | 2021 | 527 | 0.140 |
Why?
| | Radionuclide Imaging | 1 | 2016 | 121 | 0.140 |
Why?
| | Infant, Newborn | 6 | 2014 | 5089 | 0.140 |
Why?
| | Child Abuse, Sexual | 1 | 2017 | 83 | 0.140 |
Why?
| | Cross-Cultural Comparison | 1 | 2016 | 78 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 492 | 0.140 |
Why?
| | Interleukin-1beta | 1 | 2018 | 370 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2022 | 12616 | 0.140 |
Why?
| | Feces | 1 | 2018 | 374 | 0.140 |
Why?
| | Adrenal Glands | 1 | 2016 | 72 | 0.140 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2018 | 141 | 0.130 |
Why?
| | Patient Care Management | 1 | 2016 | 55 | 0.130 |
Why?
| | Standard of Care | 1 | 2016 | 63 | 0.130 |
Why?
| | Fear | 1 | 2018 | 296 | 0.130 |
Why?
| | Feasibility Studies | 2 | 2017 | 750 | 0.130 |
Why?
| | Mobile Applications | 1 | 2017 | 141 | 0.130 |
Why?
| | Obesity | 2 | 2018 | 2530 | 0.130 |
Why?
| | Transcriptome | 1 | 2020 | 742 | 0.120 |
Why?
| | Patient Preference | 1 | 2017 | 171 | 0.120 |
Why?
| | Testosterone | 1 | 2018 | 336 | 0.120 |
Why?
| | Ultrasonography, Prenatal | 1 | 2016 | 237 | 0.120 |
Why?
| | Fetal Development | 2 | 2018 | 248 | 0.120 |
Why?
| | Astronauts | 1 | 2014 | 18 | 0.120 |
Why?
| | Placebos | 2 | 2013 | 198 | 0.120 |
Why?
| | Behavioral Research | 1 | 2014 | 34 | 0.120 |
Why?
| | Urban Population | 1 | 2017 | 407 | 0.120 |
Why?
| | Poverty | 1 | 2018 | 444 | 0.120 |
Why?
| | Mental Recall | 1 | 2015 | 173 | 0.110 |
Why?
| | Gyrus Cinguli | 1 | 2014 | 69 | 0.110 |
Why?
| | Ultrasonography, Doppler | 1 | 2014 | 105 | 0.110 |
Why?
| | Drug Therapy, Combination | 5 | 2006 | 961 | 0.110 |
Why?
| | Weight Loss | 1 | 2018 | 632 | 0.110 |
Why?
| | Patient Satisfaction | 2 | 2014 | 585 | 0.110 |
Why?
| | Space Flight | 1 | 2014 | 123 | 0.110 |
Why?
| | Circadian Rhythm | 3 | 2014 | 372 | 0.110 |
Why?
| | Psychotherapy, Brief | 1 | 2013 | 30 | 0.110 |
Why?
| | Histones | 1 | 2018 | 539 | 0.110 |
Why?
| | Acute Disease | 2 | 2020 | 917 | 0.110 |
Why?
| | Mental Health Services | 1 | 2017 | 326 | 0.110 |
Why?
| | Rodentia | 1 | 2013 | 43 | 0.110 |
Why?
| | Brachial Artery | 1 | 2014 | 174 | 0.110 |
Why?
| | Behavior | 2 | 2020 | 91 | 0.110 |
Why?
| | Frontal Lobe | 1 | 2014 | 140 | 0.110 |
Why?
| | Brain Chemistry | 2 | 2007 | 116 | 0.110 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 324 | 0.110 |
Why?
| | Infant, Low Birth Weight | 1 | 2013 | 125 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2598 | 0.100 |
Why?
| | Placenta | 1 | 2018 | 623 | 0.100 |
Why?
| | Heart Rate | 1 | 2016 | 698 | 0.100 |
Why?
| | Delirium | 1 | 2013 | 66 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 545 | 0.100 |
Why?
| | Disease Management | 1 | 2015 | 562 | 0.100 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2011 | 4 | 0.100 |
Why?
| | Alzheimer Disease | 1 | 2016 | 450 | 0.100 |
Why?
| | Diet | 1 | 2018 | 1075 | 0.100 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 551 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1359 | 0.100 |
Why?
| | Patients | 1 | 2013 | 164 | 0.100 |
Why?
| | Peripartum Period | 1 | 2011 | 9 | 0.100 |
Why?
| | Body Weight | 2 | 2018 | 872 | 0.100 |
Why?
| | Vasodilation | 1 | 2014 | 413 | 0.100 |
Why?
| | Prescription Drugs | 1 | 2013 | 116 | 0.100 |
Why?
| | Functional Neuroimaging | 1 | 2011 | 67 | 0.100 |
Why?
| | Projection | 1 | 2010 | 3 | 0.090 |
Why?
| | Pregnancy, High-Risk | 1 | 2010 | 12 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2010 | 686 | 0.090 |
Why?
| | Psychoanalytic Therapy | 1 | 2010 | 10 | 0.090 |
Why?
| | Electron Transport Chain Complex Proteins | 1 | 2010 | 18 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2016 | 3054 | 0.090 |
Why?
| | Psychomotor Performance | 2 | 2011 | 278 | 0.090 |
Why?
| | Object Attachment | 1 | 2010 | 34 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3582 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2012 | 182 | 0.090 |
Why?
| | Apoptotic Protease-Activating Factor 1 | 1 | 2010 | 2 | 0.090 |
Why?
| | Menarche | 1 | 2010 | 50 | 0.090 |
Why?
| | Boston | 2 | 2020 | 76 | 0.090 |
Why?
| | Parturition | 1 | 2010 | 56 | 0.090 |
Why?
| | Mutation | 1 | 2020 | 3371 | 0.090 |
Why?
| | Brain Mapping | 3 | 2020 | 524 | 0.090 |
Why?
| | Professional-Patient Relations | 1 | 2010 | 143 | 0.080 |
Why?
| | Seasons | 1 | 2011 | 458 | 0.080 |
Why?
| | Fluvoxamine | 3 | 1999 | 12 | 0.080 |
Why?
| | Follicular Phase | 2 | 2014 | 37 | 0.080 |
Why?
| | Antimanic Agents | 1 | 2009 | 15 | 0.080 |
Why?
| | Estrogen Replacement Therapy | 2 | 2015 | 116 | 0.080 |
Why?
| | Nitric Oxide | 1 | 2014 | 834 | 0.080 |
Why?
| | Critical Care | 1 | 2013 | 476 | 0.080 |
Why?
| | Triazines | 1 | 2009 | 38 | 0.080 |
Why?
| | Age of Onset | 1 | 2010 | 455 | 0.080 |
Why?
| | Alleles | 2 | 2010 | 818 | 0.080 |
Why?
| | Time Factors | 3 | 2018 | 6186 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2014 | 771 | 0.080 |
Why?
| | Recurrence | 2 | 2013 | 949 | 0.080 |
Why?
| | Fetal Growth Retardation | 1 | 2013 | 468 | 0.080 |
Why?
| | Logistic Models | 1 | 2013 | 1865 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6438 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 964 | 0.080 |
Why?
| | Interviews as Topic | 1 | 2010 | 594 | 0.080 |
Why?
| | Amino Acids | 1 | 2011 | 455 | 0.080 |
Why?
| | Odds Ratio | 1 | 2010 | 969 | 0.070 |
Why?
| | Aspartic Acid | 2 | 2005 | 79 | 0.070 |
Why?
| | Azetidines | 1 | 2007 | 31 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 636 | 0.070 |
Why?
| | Drug Combinations | 2 | 2018 | 288 | 0.070 |
Why?
| | Administration, Intranasal | 2 | 1996 | 76 | 0.070 |
Why?
| | Arousal | 1 | 2007 | 153 | 0.070 |
Why?
| | Gonadal Disorders | 1 | 2006 | 1 | 0.070 |
Why?
| | Photic Stimulation | 1 | 2007 | 203 | 0.070 |
Why?
| | Dehydroepiandrosterone | 1 | 2006 | 49 | 0.070 |
Why?
| | Verbal Learning | 1 | 2006 | 63 | 0.070 |
Why?
| | Hormones | 1 | 2006 | 132 | 0.060 |
Why?
| | Medication Adherence | 1 | 2010 | 536 | 0.060 |
Why?
| | Receptors, Nicotinic | 1 | 2007 | 275 | 0.060 |
Why?
| | Suicidal Ideation | 2 | 2022 | 399 | 0.060 |
Why?
| | Visual Perception | 1 | 2006 | 141 | 0.060 |
Why?
| | Health Surveys | 2 | 2019 | 449 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1548 | 0.060 |
Why?
| | Cotinine | 1 | 2005 | 69 | 0.060 |
Why?
| | Androsterone | 1 | 2023 | 2 | 0.060 |
Why?
| | Pyridines | 1 | 2007 | 425 | 0.060 |
Why?
| | Ketanserin | 1 | 2003 | 12 | 0.060 |
Why?
| | Chronic Disease | 2 | 2020 | 1602 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2207 | 0.060 |
Why?
| | Half-Life | 1 | 2003 | 145 | 0.060 |
Why?
| | Receptors, Serotonin | 1 | 2003 | 32 | 0.060 |
Why?
| | Statistics as Topic | 1 | 2004 | 299 | 0.060 |
Why?
| | Child, Preschool | 1 | 2017 | 9175 | 0.050 |
Why?
| | Facial Expression | 1 | 2023 | 65 | 0.050 |
Why?
| | Heterosexuality | 1 | 2023 | 30 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1403 | 0.050 |
Why?
| | Saliva | 1 | 2004 | 189 | 0.050 |
Why?
| | Fetal Blood | 1 | 2004 | 268 | 0.050 |
Why?
| | Anisotropy | 1 | 2022 | 62 | 0.050 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2021 | 15 | 0.050 |
Why?
| | Washington | 1 | 2022 | 136 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2022 | 67 | 0.050 |
Why?
| | Synaptic Transmission | 2 | 2020 | 232 | 0.050 |
Why?
| | Gray Matter | 1 | 2022 | 65 | 0.050 |
Why?
| | Biology | 1 | 2022 | 79 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2020 | 44 | 0.050 |
Why?
| | Infant | 2 | 2004 | 8002 | 0.050 |
Why?
| | alpha-Methyltyrosine | 1 | 1999 | 2 | 0.040 |
Why?
| | RNA, Transfer | 1 | 2020 | 119 | 0.040 |
Why?
| | Independent Living | 1 | 2020 | 84 | 0.040 |
Why?
| | Dysuria | 1 | 2019 | 1 | 0.040 |
Why?
| | Teaching Materials | 1 | 1999 | 25 | 0.040 |
Why?
| | Catecholamines | 1 | 1999 | 97 | 0.040 |
Why?
| | Alcoholism | 1 | 2005 | 717 | 0.040 |
Why?
| | Urinary Incontinence | 1 | 2019 | 58 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 319 | 0.040 |
Why?
| | Neural Pathways | 1 | 2020 | 260 | 0.040 |
Why?
| | Genes, X-Linked | 1 | 2018 | 17 | 0.040 |
Why?
| | Philadelphia | 1 | 2018 | 46 | 0.040 |
Why?
| | Personality Inventory | 2 | 2013 | 135 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 77 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 546 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 389 | 0.040 |
Why?
| | Histone Code | 1 | 2018 | 29 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 162 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2020 | 216 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2018 | 204 | 0.040 |
Why?
| | Restraint, Physical | 1 | 2018 | 92 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 2006 | 953 | 0.040 |
Why?
| | Control Groups | 1 | 2017 | 10 | 0.040 |
Why?
| | Reproduction | 1 | 1999 | 180 | 0.040 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 33 | 0.040 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2014 | 72 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 215 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 1999 | 321 | 0.040 |
Why?
| | Anhedonia | 1 | 2017 | 9 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.040 |
Why?
| | Genetic Linkage | 1 | 1998 | 314 | 0.040 |
Why?
| | Patient Health Questionnaire | 1 | 2017 | 20 | 0.040 |
Why?
| | Membrane Transport Proteins | 1 | 1998 | 137 | 0.040 |
Why?
| | Placebo Effect | 1 | 2017 | 51 | 0.040 |
Why?
| | Public Health | 1 | 2021 | 439 | 0.040 |
Why?
| | Pulse | 1 | 1996 | 27 | 0.040 |
Why?
| | Workplace | 1 | 2018 | 222 | 0.030 |
Why?
| | Trophoblasts | 1 | 2018 | 162 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2018 | 196 | 0.030 |
Why?
| | Paraventricular Hypothalamic Nucleus | 1 | 2016 | 36 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 263 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 374 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 758 | 0.030 |
Why?
| | Reference Standards | 1 | 2016 | 161 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 429 | 0.030 |
Why?
| | Ambulatory Care | 1 | 1999 | 480 | 0.030 |
Why?
| | Observer Variation | 1 | 2016 | 299 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 175 | 0.030 |
Why?
| | Organ Size | 1 | 2016 | 435 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 343 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.030 |
Why?
| | Corticosterone | 1 | 2016 | 248 | 0.030 |
Why?
| | Hot Flashes | 1 | 2015 | 72 | 0.030 |
Why?
| | Aerospace Medicine | 1 | 2014 | 19 | 0.030 |
Why?
| | Connecticut | 1 | 2014 | 21 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 1998 | 538 | 0.030 |
Why?
| | MicroRNAs | 1 | 2020 | 610 | 0.030 |
Why?
| | Choline | 2 | 2005 | 108 | 0.030 |
Why?
| | Weightlessness | 1 | 2014 | 75 | 0.030 |
Why?
| | Suicide, Attempted | 1 | 2017 | 316 | 0.030 |
Why?
| | Massachusetts | 1 | 2014 | 138 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1998 | 703 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.030 |
Why?
| | Parity | 1 | 2014 | 99 | 0.030 |
Why?
| | Multimedia | 1 | 2013 | 10 | 0.030 |
Why?
| | San Francisco | 1 | 2013 | 56 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 162 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2014 | 137 | 0.030 |
Why?
| | Group Processes | 1 | 2013 | 53 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1842 | 0.030 |
Why?
| | Attitude | 1 | 2014 | 231 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1333 | 0.030 |
Why?
| | Mice | 2 | 2018 | 15075 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 476 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2014 | 460 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 541 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1023 | 0.020 |
Why?
| | Blood Pressure | 1 | 1996 | 1536 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 617 | 0.020 |
Why?
| | Population Groups | 1 | 2010 | 58 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 2861 | 0.020 |
Why?
| | Internet | 1 | 2013 | 596 | 0.020 |
Why?
| | Risk Assessment | 2 | 2014 | 3004 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1216 | 0.020 |
Why?
| | Dopamine Antagonists | 2 | 2000 | 22 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 513 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 934 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 754 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 605 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 824 | 0.020 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 101 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 4769 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 2091 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2007 | 324 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2007 | 188 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2120 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 6267 | 0.020 |
Why?
| | Creatine | 1 | 2005 | 52 | 0.020 |
Why?
| | Fluorine Radioisotopes | 1 | 2003 | 11 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 2003 | 58 | 0.010 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2003 | 19 | 0.010 |
Why?
| | Pyramidal Cells | 1 | 2003 | 51 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2581 | 0.010 |
Why?
| | Tics | 1 | 2000 | 2 | 0.010 |
Why?
| | Schizotypal Personality Disorder | 1 | 2000 | 8 | 0.010 |
Why?
| | Models, Neurological | 1 | 2002 | 213 | 0.010 |
Why?
| | Treatment Failure | 1 | 1999 | 333 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2000 | 724 | 0.010 |
Why?
| | 1-Naphthylamine | 1 | 1996 | 1 | 0.010 |
Why?
| | Clomipramine | 1 | 1996 | 2 | 0.010 |
Why?
| | Buspirone | 1 | 1996 | 4 | 0.010 |
Why?
| | Clonazepam | 1 | 1996 | 5 | 0.010 |
Why?
| | Paroxetine | 1 | 1996 | 7 | 0.010 |
Why?
| | Fenfluramine | 1 | 1996 | 13 | 0.010 |
Why?
| | Lithium | 1 | 1996 | 36 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1226 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1996 | 79 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1996 | 200 | 0.010 |
Why?
| | Drug Interactions | 1 | 1996 | 347 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1998 | 634 | 0.010 |
Why?
|
|
Epperson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|